Suppr超能文献

临床肿瘤学的《回到未来》

Back to the Future for Clinical Oncology.

作者信息

Chabner BA

机构信息

Department of Hematology/Oncology, Massachusetts General Hospital, Cambridge, Massachusetts, 02114-2617, USA.

出版信息

Oncologist. 1996;1(1 & 2):I.

Abstract

Dear Colleague: I remember, but just barely, what it was like to practice medicine in the first half of this century. My Dad was a general practitioner in a very small farming community in central Illinois, with a hospital of six beds and a trusting clientele. His patients thought he knew how to do everything: deliver babies, set broken bones and take out an appendix. He was an advocate for his patients, not for an HMO or an insurance company. He derived great satisfaction from his practice and was comfortable in this role, up to a point, but knew that he frequently needed the help of specialists from Decatur, St. Louis, and the Mayo Clinic. As his experience and practice evolved, and as medicine itself changed, referrals became a sign of good practice and not an indication of weakness or inadequacy. Some doctors in our town continued to do more than they should have and resisted the trend, and their patients, many with blind faith in their doctor, suffered for it. Clearly, there were economic as well as emotional factors that contributed to this reluctance to ask for help. Clinical oncology is facing much the same situation today. Scientific and economic forces are revolutionizing medicine, but not always in compatible directions. Practice and research have evolved to the point where old patterns of practice are no longer optimal. Few cancer patients can be managed without the input, advice, and even direct involvement of specialists from sister disciplines. Thus, multimodality management of cancer patients is now the norm rather than the exception. At the same time, strong economic forces are dictating a movement in the opposite direction, undermining the strength of traditional academic centers and limiting choices, streamlining patient evaluation, and creating "pathways" to standardize patient management. Who should be setting the course for the cancer patient? We agree that it should not be a clerk at the other end of the phone at the HMO, a computerized practice manual, or even the gatekeeper, who watches his or her capitated bottom line with great nervousness. It should be the physician(s) best able to evaluate the alternatives and communicate these choices to the patient and family. Often it is not possible for a solo physician to make these choices in isolation, particularly when the decisions involve multiple specialties and multimodality therapies. At presentation, many primary cancers now require an integration of the opinion of more than one specialist, and increasingly this integration occurs before surgery. Breast, lung, and prostate cancer, three of our most common diseases, illustrate this point with growing clarity. While less convenient for the doctor, and perhaps less efficient than the "old style" of practice, multimodatity disease center clinics offer significant advantages both to the patient and to the research effort, and are here to stay. Certainly for the payer it is faster and cheaper to have one doctor do it all, but I doubt that the results will be as good. Obviously not all patients need this cooperative approach. It would waste good physicians' time to require that all patients be seen by a radiotherapist, surgeon, and medical oncologist or pediatric oncologist. The specific circumstances may clearly dictate a simple approach and an uncomplicated decision, particularly in dealing with metastatic solid tumors, or at the other extreme, in managing easily resectable, low-risk tumors. However, even here, optimal management of local disease or of potentially resectable metastases may require consideration of an expanded series of options. Thus, all cancer specialists need to be aware of the potential of their colleagues to contribute to disease management. ellipsisWhich brings us to the reason for this journal. The editorial board members of The Oncologist hold the belief that the various subspecialists in oncology should share the same information base and read from the same journal. We believe that cancer specialists should resist the trend to capitulate our responsibilities in disease management to payers, gatekeepers, and hospital administrators. It is up to us to defend the patient's turf and to assure that the patient has an advocate. In order to do so, we will have to be united and fully informed. In this journal, we hope to put the best and latest information on cancer management before our readership, to prepare them for the future, and to do their best as a team for every patient. To this end, we hope to challenge the reader to understand what is new and better, and to let you glimpse the future, not only in terms of research, but also in terms of new team approaches to disease management. We hope to explore how cancer medicine could be and will be practiced as we pass through the economic revolution and return to the future.

摘要

亲爱的同事

我还记得,只是勉强记得,在本世纪上半叶行医是什么样子。我父亲是伊利诺伊州中部一个非常小的农业社区的全科医生,那里有一家六张床位的医院和一群信任他的病人。他的病人认为他无所不能:接生婴儿、接骨和切除阑尾。他是病人的拥护者,而不是健康维护组织(HMO)或保险公司的拥护者。他从行医中获得了极大的满足感,并且在一定程度上对这个角色感到自在,但他知道自己经常需要来自迪凯特、圣路易斯和梅奥诊所的专家的帮助。随着他的经验和实践的发展,以及医学本身的变化,转诊成为良好医疗实践的标志,而不是软弱或不足的表现。我们镇上的一些医生继续做着超出他们能力范围的事情,并抵制这种趋势,他们那些对医生盲目信任的病人为此受苦。显然,有经济和情感因素导致了这种不愿寻求帮助的情况。

临床肿瘤学如今面临着大致相同的情况。科学和经济力量正在彻底改变医学,但并不总是朝着一致的方向发展。实践和研究已经发展到旧的医疗模式不再是最佳选择的地步。很少有癌症患者能够在没有姐妹学科专家的参与、建议甚至直接介入的情况下得到妥善治疗。因此,癌症患者的多学科管理现在是常态而非例外。与此同时,强大的经济力量正朝着相反的方向推动,削弱了传统学术中心的实力,限制了选择,简化了患者评估,并创建了“路径”以规范患者管理。

谁应该为癌症患者设定治疗方向呢?我们一致认为,不应该是健康维护组织电话另一端的办事员、计算机化的医疗手册,甚至是那个紧张地盯着按人头付费底线的把关人。应该是最有能力评估各种选择并将这些选择传达给患者及其家属的医生。通常,单个医生不可能孤立地做出这些选择,尤其是当决策涉及多个专科和多学科治疗时。在初次就诊时,许多原发性癌症现在需要整合不止一位专家的意见,而且越来越多的情况是在手术前就进行这种整合。乳腺癌、肺癌和前列腺癌,这三种我们最常见的疾病,越来越清楚地说明了这一点。

虽然对医生来说不太方便,而且可能不如“老式”医疗模式高效,但多学科疾病中心诊所对患者和研究工作都有显著优势,并且会持续存在。当然,对付款人来说,让一位医生包办一切更快、更便宜,但我怀疑结果是否会同样好。显然,并非所有患者都需要这种合作方式。要求所有患者都由放射肿瘤学家、外科医生和医学肿瘤学家或儿科肿瘤学家诊治,会浪费优秀医生的时间。具体情况可能明确表明需要一种简单的方法和不复杂的决策,特别是在处理转移性实体瘤时,或者在另一个极端,在管理易于切除的低风险肿瘤时。然而,即使在这里,对局部疾病或潜在可切除转移灶的最佳管理可能也需要考虑一系列更广泛的选择。因此,所有癌症专家都需要了解他们的同事对疾病管理做出贡献 的潜力。

……

这就引出了这本期刊的创办初衷。《肿瘤学家》的编辑委员会成员认为,肿瘤学的各个亚专科应该共享相同的信息基础,并阅读同一本期刊。我们认为,癌症专家应该抵制将我们在疾病管理中的责任让渡给付款人、把关人和医院管理人员的趋势。捍卫患者的权益并确保患者有拥护者是我们的责任。为了做到这一点,我们必须团结起来并充分了解情况。在这本期刊中,我们希望将有关癌症管理的最佳和最新信息呈现给我们的读者,使他们为未来做好准备,并作为一个团队为每一位患者竭尽全力。为此,我们希望激发读者去理解什么是新的、更好的,并让您瞥见未来,不仅是在研究方面,而且是在疾病管理的新团队方法方面。我们希望探讨在我们经历经济变革并回归未来的过程中,癌症医学能够并且将会如何实践。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验